SCHEMBL4367694

SCHEMBL4367694

CN(Nc1cc(F)ccc1C(F)(F)F)C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
XPO1 O14980 1/20 0.36
CACNA1G O43497 1/20 0.36
CACNA1B Q00975 1/20 0.36
CACNA1C Q13936 1/20 0.36
CRHR1 P34998 1/20 0.36
HTT P42858 2/20 0.35
ALOX15 P16050 1/20 0.34
KMT2A Q03164 1/20 0.34
ATM Q13315 1/20 0.34
KDR P35968 1/20 0.34
TEK Q02763 1/20 0.34
NOTUM Q6P988 1/20 0.34
RAB9A P51151 1/20 0.34
P2RY1 P47900 1/20 0.33
POLQ O75417 1/20 0.33
MAPK10 P53779 1/20 0.33
RXRA P19793 1/20 0.33
NR1H2 P55055 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4369647 0.87 MAPT (0.42) POLBHTTKMT2AKCNQ4KCNQ5
SCHEMBL4369944 0.86 CES2 (0.42) LMNAPOLBXPO1CACNA1GCACNA1B
SCHEMBL4367386 0.84 CLCN2 (0.36) HTTALOX15KMT2A
SCHEMBL30291804 0.81 HDAC1 (0.43) HTTALOX15KCNQ4KCNQ5
SCHEMBL4367290 0.80 CACNA1B (0.42) LMNAPOLBCACNA1GCACNA1BCACNA1C
SCHEMBL4365064 0.78 MEN1 (0.44) KMT2AKDRRXRANR1H2NR1H3
SCHEMBL30291778 0.77 KCNMA1 (0.44) KMT2ARAB9A
SCHEMBL4364565 0.76 MEN1 (0.44) LMNAPOLBKMT2AATMRAB9A
SCHEMBL29307526 0.74 CFTR (0.47) CACNA1GCACNA1BCACNA1CALOX15KMT2A
SCHEMBL30196043 0.74 CFTR (0.47) CACNA1GCACNA1BCACNA1CALOX15KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1924563-B1 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 HOFFMANN LA ROCHE (CH) 2013-07-31 EP disclosed
CN-101253155-B 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 HOFFMANN LA ROCHE 2011-11-09 CN disclosed
US-7622492-B2 Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2009-11-24 US disclosed
US-7622492-B2 Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2009-11-24 US disclosed
US-7622492-B2 Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2009-11-24 US disclosed
CN-101253155-A 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 HOFFMANN LA ROCHE (CH) 2008-08-27 CN disclosed
EP-1924563-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP disclosed
WO-2007025892-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
WO-2007025892-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
US-20070049632-A1 Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase BANNER BRUCE L 2007-03-01 US disclosed
US-20070049632-A1 Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase BANNER BRUCE L 2007-03-01 US disclosed
US-20070049632-A1 Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase BANNER BRUCE L 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049632-A1 Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase HSD17B1, HSD17B2, HSD3B2 LMNA 3237/4885POLB 1084/4885XPO1 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.